Abstract. Dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein (DC-SIGNR) is a type II transmembrane protein that has been reported to bind to various pathogens and participate in immunoregulation and tumorigenesis. However, further research is required to investigate whether the level of DC-SIGNR and cervical cancer are associated. The present study aimed to explore the clinical diagnostic significance of DC-SIGNR in cervical cancer. Immunohistochemical staining of DC-SIGNR was performed in samples from 25 patients with early stage cervical cancer, 14 patients with cervical intraepithelial neoplasia (CIN) and cervical polyp samples from 15 individuals. DC-SIGNR expression in cervical cancer tissue was significantly higher compared with that in CIN and cervical polyp tissue (P=0.0184 and P=0.0236, respectively). However, there was no significant difference in DC-SIGNR expression between CIN and cervical polyp tissue (P=0.8103). Additionally, the serum DC-SIGNR levels in 84 cervical cancer patients and 69 healthy female individuals were measured using an ELISA. Serum (s)DC-SIGNR levels were significantly higher in cervical cancer patients compared with healthy female individuals (P<0.0001). A sDC-SIGNR level of 93.7 ng/ml was revealed by receiver operating characteristic curve analysis to predict the presence of cervical cancer with 69.57% sensitivity and 66.67% specificity (area under the curve, 0.6989; P<0.0001). Levels of sDC-SIGNR in cervical cancer patients were also correlated with serum levels of squamous cell carcinoma antigen (r=0.2583; P=0.0348). The results of the present study demonstrate that DC-SIGNR is overexpressed in cervical cancer tissue, and suggest that DC-SIGNR could serve as a biomarker for the early diagnosis of cervical cancer. Nevertheless, further studies are required to demonstrate what role DC-SIGNR serves in cervical cancer.
Introduction
Cervical cancer is the second most common malignancy in women (1) and has a significant impact on their health and lives (2) . According to the World Health Organization, 266,000 women worldwide die of cervical cancer annually. Cervical cancer is the most common cancer among women in 45 different countries; these include countries in sub-Saharan Africa, Asia, including India, and certain Central and South American countries (3) . A variety of factors contribute to cervical cancer occurrence and development; for example, the high-risk human papilloma virus (4, 5) . Cervical cancer susceptibility is also increased by host genetic factors (6) . Additionally, there are other biological molecules that are correlated with the risk of cervical cancer, such as forkhead box protein P3 (7) .
C-type lectins, a large superfamily of proteins, have been reported to serve important roles in immunity, cell death and tumorigenesis (8) (9) (10) (11) . Dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein (DC-SIGN) is a membrane-bound member of the C-type lectin superfamily that is expressed in dendritic cells, monocyte-derived dendritic cells and specialized macrophages in vitro (12) . The genes encoding DC-SIGN and its homologue DC-SIGN-related protein (DC-SIGNR) are located on human chromosome 19p13. 3 , and belong to a subfamily in the lectin gene cluster along with cluster of differentiation (CD) 23 and Overexpression of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein in cervical cancer and correlation with squamous cell carcinoma antigen liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin) (13) (14) (15) . DC-SIGN is also expressed in the endothelial cells of the hepatic sinusoid and lymphatic sinus (16) . DC-SIGN expression is associated with colorectal cancer (17) and non-Hodgkin's lymphoma (NHL) (18) ; thus DC-SIGN may be useful in a clinical setting (18) . Since DC-SIGNR and DC-SIGN share a 77% structural similarity (19) , their function may be similar. DC-SIGNR is highly expressed in endothelial cells in the placenta, liver and lymph nodes (20) , but is expressed at lower levels in NHL and lung cancer (18, 21) . In addition, a previous study reported that serum concentrations of DC-SIGNR were higher in brain metastatic compared with in non-metastatic lung cancer (21) . However, an association between DC-SIGNR and cervical cancer has not been reported, to the best of our knowledge. In the present study, the tissue expression of DC-SIGNR and levels of serum (s)DC-SIGNR in patients with cervical cancer were investigated in order to determine whether sDC-SIGNR could be used as biomarker for the detection of cervical cancer. Additionally, the association between the expression of DC-SIGNR and squamous cell carcinoma antigen (SCC-Ag), the serum marker typically used for the clinical monitoring of cervical cancer, was measured (22) . Immunohistochemistry. Sections from paraffin-embedded blocks of each tissue sample were incubated at 60˚C for 30 min. The paraffin was removed with xylene and the samples were rehydrated in a graded ethanol series. Tissue sections (5 µm thick) were washed with PBS and endogenous peroxidase activity was blocked with 3% hydrogen peroxide diluted in double-distilled water for 10 min at room temperature. Antigen retrieval was performed by heating the slides in 0.01 mol/l citrate-buffered solution (pH 6.0) for 20 min in a microwave oven. Following antigen retrieval, sections were washed with PBS and blocked with goat serum (ZSGB-BIO, Beijing, China) for 20 min at the room temperature. An anti-DC-SIGNR rabbit polyclonal antibody (cat. no. ab169783; dilution, 1:150; Abcam, Cambridge, UK) was incubated with sections overnight at 4˚C. The next day, sections were washed 3 times in PBS (5 min/wash). Then, the sections were incubated for 1 h at 37˚C with a horseradish peroxidase-labeled anti-rabbit secondary antibody (1:1,000) and washed 3 times in PBS. The sections were developed by applying 3,3'-diaminobenzidine tetrahydrochloride (ZSGB-BIO) to the sections and then counterstaining with hematoxylin. An Olympus BX51 microscope (Olympus Corporation, Tokyo, Japan) was used to capture images of all sections. The mean density of the DC-SIGNR expression was obtained using Image-Pro Plus software (version 6.0; Media Cybernetics, Inc., Rockville, MD, USA).
Materials and methods

Clinical
ELISA. An anti-DC-SIGNR goat polyclonal antibody (cat. no. sc-17261; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) was used at a final concentration of 0.27 µg/ml to coat 96-well microplates before incubating the plates overnight at 4˚C. The next day, the plates were washed 3 times with PBS containing 0.05% Tween-20 (PBST; pH 7.4), and the wells were blocked with 5% bovine serum albumin (cat. no. Roche1073507801; BIOSHSARP, Inc., Hefei, China) at 37˚C for 1 h. Following 3 washes with PBST, 100 µl of serum from patients with cervical cancer and healthy individuals were added to the wells, using 100 µl PBS as a negative control. Each plate was incubated at 37˚C for 1 h, and then the wells were washed 3 times with PBST before adding 100 µl anti-DC-SIGNR mouse monoclonal antibody (cat. no. MAB16211; R&D Systems, Inc., Minneapolis, MN, USA), diluted to a concentration of 0.5 µg/ml, to each well. The plates were incubated at 37˚C for 1.5 h, and then the wells were washed 3 times with PBST. Following the PBS wash, 100 µl of a peroxidase-conjugated goat anti-mouse antibody (cat. no. ZB-2305; dilution, 1:1,500; ZSGB-BIO) was added and the plates were incubated for 60 min at 37˚C. The plates were washed 3 times with PBST and 3,3' ,5,5'-tetramethylbenzidine (Tiangen Biotech Co., Ltd., Beijing, China) was added to each well prior to incubation at 37˚C for 30 min. Finally, 2 mol/l H 2 SO 4 was added to stop the reaction. The optical density (OD) was measured on a microplate reader at a wavelength of 450 nm. The sDC-SIGNR concentration in each sample was calculated by comparing the OD values with a standard curve.
Statistical analysis.
A non-parametric Mann-Whitney U test was used to determine the statistical significance between groups in the immunohistochemical and ELISA analyses. A non-parametric Spearman's rank correlation coefficient test was performed to measure the correlation of sDC-SIGNR with SCC-Ag levels and other clinical parameters. Receiver operating characteristic (ROC) curve analysis was applied to assess the diagnostic value of sDC-SIGNR in cervical cancer. All statistical analyses were performed using GraphPad Prism 5 software (version 5; GraphPad Software, Inc., La Jolla, CA, USA).
Results
DC-SIGNR mean density is significantly increased in cervical cancer tissue compared with CIN and cervical polyp tissue.
Immunohistochemical staining was used to explore whether DC-SIGNR is overexpressed in cervical cancer (Fig. 1) . Previous studies have demonstrated that DC-SIGNR is expressed in normal lymph nodes (24) , therefore normal lymph node tissue was included as a positive control (Fig. 1A) . Staining of cervical tissue samples from 25 patients with cervical cancer, 14 patients with CIN and 15 patients with cervical polyps revealed that DC-SIGNR was overexpressed in cervical cancer tissue (Fig. 1C) . The mean density of DC-SIGNR in cervical cancer tissue was significantly higher compared with CIN and cervical polyp tissue (P=0.0184 and P=0.0236, respectively; Fig. 1F) ; however, there was no significant difference between the mean density of DC-SIGNR expression in CIN and cervical polyp tissue (P=0.8103; Fig. 1F ). Additionally, the mean density of DC-SIGNR expression positively correlated with serum levels of SCC-Ag (r=0.5143; P=0.0203; Fig. 2A) . Furthermore, the mean density of DC-SIGNR was significantly increased in samples with serum SCC-Ag levels higher compared with the normal range (P=0.0433; Fig. 2B ). However, there was no correlation between serum LDH (Fig. 2C and D) , ALP (Fig. 2E and F) , or CD3, 4, and 8 levels (data not shown) and the mean density of The results indicate the number of patients for whom data were available. CIN, cervical intraepithelial neoplasia; SCC-Ag, squamous cell carcinoma antigen.
DC-SIGNR. There was no significant difference between the mean density of DC-SIGNR in cervical cancer samples that were well differentiated compared with samples that exhibited low differentiation (P=0.9650; Fig. 3A ) (25) . Additionally, there was no significant difference between the mean density of DC-SIGNR in cervical cancer tissue from patients who were ≥50 years old and patients who were <50 years old (P=0.6229; Fig. 3B ).
Levels of sDC-SIGNR are significantly higher in patients with cervical cancer compared with healthy individuals.
Using an ELISA, the sDC-SIGNR levels of 84 patients with cervical cancer and 69 healthy individuals were compared. Levels of sDC-SIGNR in patients with cervical cancer were significantly higher compared with those in healthy individuals (P<0.0001; Fig. 4A ). Concentrations of sDC-SIGNR ranged from 29.64-769.5 ng/ml (mean, 132.1 ng/ml) in patients with cervical cancer and from 16.76-515.8 ng/ml (mean, 96.28 ng/ml) in healthy individuals. A ROC curve is frequently used to evaluate the power of a novel serum marker to predict the presence of tumors. In the present study, a cut-off value of 93.7 ng/ml for sDC-SIGNR was identified to predict the presence of cervical cancer with 69.57% sensitivity and 66.67% specificity (P<0.0001; Fig. 4B ).
Levels of sDC-SIGNR are higher in stage I and II cervical cancer compared with stage III and IV cervical cancer.
Excluding 2 patients with CIN III, levels of sDC-SIGNR were compared between 60 patients with stage I-II and 22 patients with III-IV cervical cancer, where stages I-II correspond to earlier stages of disease progression and would therefore have a better prognosis. Levels of sDC-SIGNR in patients with stage I and II cervical cancer were significantly higher than in patients with stage III and IV cervical cancer (P=0.0336; Fig. 4C ). There was no statistical significance between sDC-SIGNR levels in stage III and IV patients compared with healthy individuals (P=0.0759; Fig. 4C ). These results suggest that sDC-SIGNR could be used as a biomarker for the early diagnosis of cervical cancer. However, there was no significant difference in sDC-SIGNR levels in patients with metastatic cervical cancer compared with patients with non-metastatic cervical cancer (P=0.1793; Fig. 4D ).
Levels of sDC-SIGNR positively correlate with serum levels
of SCC-Ag. SCC-Ag serves as a prognostic marker for cervical cancer (26); patients with cervical cancer present with higher levels of serum SCC-Ag compared with healthy individuals (27) . Therefore, the association between serum SCC-Ag and sDC-SIGNR levels were analyzed in the group of patients with cervical cancer. Notably, there was a positive correlation between the levels of serum SCC-Ag and sDC-SIGNR (r=0.2583; P=0.0348; Fig. 4E ). The levels of sDC-SIGNR were significantly higher in samples with high serum SCC-Ag levels compared with samples with normal serum SCC-Ag levels (P=0.0426; Fig. 4F ).
There is no association between sDC-SIGNR levels and the levels of serum CEA or . Levels of sDC-SIGNR were not associated with age (r=-0.1172; P=0.2883; Fig. 5A ), and there was no statistically significant difference between sDC-SIGNR levels in patients aged ≥50 and <50 (P=0.7944; Fig. 5B ). There was no association between sDC-SIGNR levels and the levels of serum CEA (r=-0.21; Correlation analysis of DC-SIGNR expression and clinical data. Graphs show (A) the correlation between the mean density of DC-SIGNR from immunohistochemistry analysis and the serum level of SCC-Ag, (B) the mean density of DC-SIGNR in patients with high SCC-Ag serum levels compared with those with normal SCC-Ag levels, (C) the correlation of the mean density of DC-SIGNR and serum ALP levels, (D) the mean density of DC-SIGNR in patients with low ALP levels compared with those with normal ALP levels, (E) the correlation of the mean density of DC-SIGNR and serum LDH levels, (F) the mean density of DC-SIGNR in patients with high LDH levels compared with those with normal LDH levels. Data are presented as the mean ± standard deviation. DC-SIGNR, dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related protein; SCC-Ag, squamous cell carcinoma antigen; ALP, alkaline phosphatase; LDH, lactate dehydrogenase. P=0.2102; Fig. 5C ), CA-199 (r=-0.2288; P=0.4121; Fig. 5D ), CA-153 (r=-0.4978; P=0.0497; Fig. 5E ) and CA-125 (r=-0.2035; P=0.3087; Fig. 5F ).
Discussion
DC-SIGNR is a member of the C-type lectin family of proteins. Previous research has focused on the association between DC-SIGNR and viral infections, including human immunodeficiency virus (HIV) (27, 28) and hepatitis B (29) . Previous studies have indicated that DC-SIGNR is highly expressed in peripheral blood mononuclear cells in patients with HIV-1 infection (30) . However the role of DC-SIGNR in cancer, particularly cervical cancer, remains unclear. In order to study the clinical value of DC-SIGNR in cervical cancer, the mean density of DC-SIGNR in the tissue of 25 patients with cervical cancer, 14 patients with CIN and 15 patients with cervical polyps was determined by immunohistochemistry. The mean density of DC-SIGNR was significantly higher in cervical cancer tissue compared with CIN and cervical polyp tissue (P=0.0184 and P=0.0236, respectively). However, there was no significant difference in the mean density between CIN and cervical polyp tissue samples (P=0.8103). This result suggests that DC-SIGNR could serve as a biomarker for the early diagnosis of cervical cancer.
The rate of recurrence of cervical cancer in patients is low; however, the sensitivity of the cancer to radiotherapy and chemotherapy is significantly decreased in cases where the cancer is recurrent (31) . SCC-Ag is a glycoprotein that belongs to the serpin family of serine/cysteine proteinase inhibitors. SCC-Ag has been associated with the prognosis of recurrent cervical squamous carcinoma (32) , and is of great significance in the prognosis and clinical diagnosis of cervical cancer (33) (34) (35) . In the present study, a correlation between the mean density of DC-SIGNR and the clinical serum SCC-Ag concentration was observed (r=0.5143; P=0.0203). However, there was no association between DC-SIGNR and other clinical markers, such as CEA and CA-199, -125 and -153.
Due to the association between DC-SIGNR levels and cervical cancer identified by immunohistochemistry, the levels of sDC-SIGNR in patients with cervical cancer were analyzed by ELISA and compared with the levels of sDC-SIGNR from healthy individuals. The level of sDC-SIGNR was higher in patients with cervical cancer compared with that in healthy individuals, and was significantly positively correlated with SCC-Ag levels. Previous studies have demonstrated that DC-SIGNR expression is lower in patients with NHL and lung cancer compared with that in healthy individuals (21, 36) ; therefore DC-SIGNR may have a clinical application for the diagnosis of a number of types of cancer. sDC-SIGNR levels in patients with stage I and II cervical cancer were significantly higher compared with those in patients with stage III and IV cervical cancer. This result suggests that DC-SIGNR is likely to be of most clinical value in the early diagnosis of cervical cancer. There was no significant difference in sDC-SIGNR levels between patients with stage III/IV cervical cancer and healthy individuals. This result may be related to the decline of immune function in the late stages of cancer.
Although pathological diagnosis remains the gold standard for the diagnosis of cervical cancer, serum tumor markers could be important for the early diagnosis of cervical cancer, particularly for high-risk screening. If cancer is detected at an early stage, or even in the pre-malignant stage, physicians will have a higher probability of successfully treating the patient (37, 38) . The results from the present study indicate that DC-SIGNR and sDC-SIGNR levels could be helpful for the early diagnosis of cervical cancer.
C-type lectins are a large family of proteins that serve roles in several biological processes. Various previous studies have demonstrated that a number of C-type lectins participate in tumor metastasis, for example LSECtin and L-selectin (39, 40) . Although the specific role DC-SIGNR serves in cervical cancer remains unclear, the results of the present study indicate that DC-SIGNR and sDC-SIGNR levels can be used to distinguish between patients with cervical cancer and healthy individuals, and may allow for the early diagnosis of cervical cancer. Further experiments are required to explore the specific roles DC-SIGNR serves in cervical cancer.
